Amneal Pharmaceuticals Inc (NASDAQ: AMRX) on Friday, plunged -3.28% from the previous trading day, before settling in for the closing price of $8.24. Within the past 52 weeks, AMRX’s price has moved between $6.50 and $9.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.70% over the past five years. The company achieved an average annual earnings per share of 21.98%. With a float of $143.72 million, this company’s outstanding shares have now reached $313.38 million.
Let’s look at the performance matrix of the company that is accounted for 8300 employees. In terms of profitability, gross margin is 36.69%, operating margin of 12.73%, and the pretax margin is 2.05%.
Amneal Pharmaceuticals Inc (AMRX) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Amneal Pharmaceuticals Inc is 54.15%, while institutional ownership is 39.71%. The most recent insider transaction that took place on Jun 16 ’25, was worth 761,146. In this transaction Director of this company sold 94,906 shares at a rate of $8.02, taking the stock ownership to the 1,609,144 shares. Before that another transaction happened on Jun 10 ’25, when Company’s Director sold 56,426 for $8.02, making the entire transaction worth $452,537. This insider now owns 1,704,050 shares in total.
Amneal Pharmaceuticals Inc (AMRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.84% during the next five years compared to 32.70% growth over the previous five years of trading.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
Amneal Pharmaceuticals Inc (AMRX) is currently performing well based on its current performance indicators. A quick ratio of 0.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.88. Likewise, its price to free cash flow for the trailing twelve months is 10.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.04, a number that is poised to hit 0.17 in the next quarter and is forecasted to reach 0.82 in one year’s time.
Technical Analysis of Amneal Pharmaceuticals Inc (AMRX)
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) saw its 5-day average volume 1.16 million, a negative change from its year-to-date volume of 1.7 million. As of the previous 9 days, the stock’s Stochastic %D was 29.84%.
During the past 100 days, Amneal Pharmaceuticals Inc’s (AMRX) raw stochastic average was set at 52.02%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was lower than the 0.29 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.78, while its 200-day Moving Average is $8.11. Nevertheless, the first resistance level for the watch stands at $8.19 in the near term. At $8.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.52. If the price goes on to break the first support level at $7.86, it is likely to go to the next support level at $7.75. The third support level lies at $7.53 if the price breaches the second support level.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Key Stats
Market capitalization of the company is 2.50 billion based on 313,420K outstanding shares. Right now, sales total 2,794 M and income totals -116,890 K. The company made 695,420 K in profit during its latest quarter, and 12,200 K in sales during its previous quarter.
